Clinical programs for inhaled insulin have received several setbacks of late, with Bagsværd, Denmark-based Novo Nordisk deciding in January to terminate phase 3 trials of its inhaler and ...

These products fall into two main groups: solution and drug powder formulations, which are delivered through different patented inhaler systems. Exubera, a rapid-acting insulin in powder form ...

Inhaled insulin is a new option for type 2 diabetic patients with poor glycemic control on oral monotherapy. A rapid-acting inhaled insulin (Exubera) was approved recently for treatment of type 1 ...

DiMarchi is the inventor of Lilly's insulin ... rapid therapeutic onset. The '477 patent issued to Aradigm covers the use of monomeric insulin as a means for improving the bioavailability of ...

Afrezza (insulin human) Inhalation Powder is a rapid-acting inhaled human insulin indicated to improve glycemic control in adults with diabetes mellitus. Limitations of Use: Not recommended for the ...

The world's largest drug maker, Pfizer has announced that it intends to fast track its inhaled insulin Exubera in India. The world's largest drug maker, Pfizer has announced that it intends to ...

Afrezza (insulin human) Inhalation Powder is a rapid-acting inhaled human insulin indicated to improve glycemic control in adults with diabetes mellitus. Limitations of Use: Not recommended for ...